Findings from this study have previously been presented at the International Society for Pharmacoeconomics and Outcomes Research 17th Annual International Meeting, Washington, DC, 2−6 June 2012.
Costs of adverse events among patients with HIV infection treated with nonnucleoside reverse transcriptase inhibitors†
Article first published online: 18 MAR 2014
© 2014 British HIV Association
Volume 15, Issue 8, pages 488–498, September 2014
How to Cite
Simpson, K., Chen, S.-Y., Wu, A., Boulanger, L., Chambers, R., Nedrow, K., Tawadrous, M., Pashos, C. and Haider, S. (2014), Costs of adverse events among patients with HIV infection treated with nonnucleoside reverse transcriptase inhibitors. HIV Medicine, 15: 488–498. doi: 10.1111/hiv.12145
- Issue published online: 19 AUG 2014
- Article first published online: 18 MAR 2014
- Manuscript Accepted: 27 JAN 2014
- adverse events;
- health care costs;
- nonnucleoside reverse transcriptase inhibitors
The aim of the study was to assess the incidence and costs of adverse events (AEs) among patients with HIV infection treated with nonnucleoside reverse transcriptase inhibitors (NNRTIs) from the health care system perspective.
US medical and pharmacy claims during 2004−2009 were examined to select adult new NNRTI users with HIV infection. The incidence of selected AEs and time to occurrence were assessed during the first year. Episodes of care for each AE were identified using claims associated with AE management. For each AE, a propensity score model was used to match patients with an AE to those without (1:4) based on the propensity of having an AE. Mean total health care costs, AE-associated costs and incremental costs per episode, and annual total health care costs per patient were calculated.
Of the 2548 NNRTI-treated patients, 29.3% experienced AEs. The incidence ranged from 0.4 episodes/1000 person-years for suicide/self-injury to 14.9 episodes/1000 person-years for dizziness, 49.8 episodes/1000 person-years for depression and 150.3 episodes/1000 person-years for lipid disorder. The mean AE-associated cost (duration) per episode ranged from $586 (88 days) for lipid disorder to $975 (33 days) for rash, $2760 (73 days) for sleep-related symptoms and $4434 (41 days) for nausea/vomiting. The mean incremental cost per episode ranged from $1580 for rash to $2032 for lipid disorder, $8307 for sleep-related symptoms and $12 833 for nausea/vomiting. During the 12 months following NNRTI initiation, the mean annual total health care cost was $27 299 (efavirenz: $26 185; other NNRTIs: $34 993) and AE-associated costs were $608 (efavirenz: $554; other NNRTIs: $979) among all NNRTI users.
With treatment increasing patient survival, comparisons of therapeutic regimens should consider treatment-associated AEs. Findings from this study could be informative for clinicians and payers in managing HIV infection with NNRTIs.